Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
(2021).
(2020).
(2019).
Antihypertensive therapy in acute ischemic stroke: where do we stand?.
J Hum Hypertens. 32(12), 799-807.
(2018). Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia..
Curr Pharm Des. 24(46), 5542-5547.
(2018). Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?.
J Clin Hypertens (Greenwich). 20(2), 255-257.
(2018). Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH)..
Atherosclerosis. 277, 308-313.
(2018). Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints..
Curr Pharm Des.
(2018). Diabetes and lipid metabolism..
Hormones (Athens). 17(1), 61-67.
(2018). Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?.
Maturitas. 108, 45-52.
(2018). Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality..
Curr Vasc Pharmacol. 16(3), 206-208.
(2018). Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis..
Curr Vasc Pharmacol. 16(2), 104-106.
(2018). The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data..
Hormones (Athens). 17(1), 83-95.
(2018). Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension..
Curr Vasc Pharmacol. 16(4), 393-400.
(2018). Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?.
J Clin Hypertens (Greenwich). 20(3), 469-471.
(2018). The potential role of statins in treating liver disease..
Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
(2018). Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?.
J Clin Hypertens (Greenwich). 20(5), 942-948.
(2018). Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?.
Open Cardiovasc Med J. 12, 29-40.
(2018). Renal resistive index for renovascular hypertension: In the quest of the Holy Grail..
J Clin Hypertens (Greenwich). 20(3), 589-591.
(2018). Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?.
J Clin Hypertens (Greenwich). 20(4), 634-636.
(2018). Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?.
J Hypertens. 36(3), 701.
(2018). What is the role of statins in the elderly population?.
Expert Rev Clin Pharmacol. 11(4), 329-331.
(2018). Editorial: The microRNA 221/222 Cluster: Inaugurating a New Era in Cardiovascular Disease and Cancer?.
Curr Vasc Pharmacol. 15(1), 47-50.
(2017). The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins..
Curr Pharm Des. 23(10), 1477-1483.
(2017). The effect of SGLT2 inhibitors on cardiovascular events and renal function..
Expert Rev Clin Pharmacol. 10(11), 1251-1261.
(2017).